No profile data available.
Absci Corporation (ABSI) is a healthcare company in the medication development research industry, based in Vancouver, United States, with about 140 full-time employees.
It reported revenue of $2.80 million for fiscal year 2025, down 38.2% from fiscal year 2024, and net income of -$115.18 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $318,000, down 46.4% from a year before. Its market capitalization was $1.74 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Absci reported $2.80 million in revenue for fiscal year 2025, down 38.2% from $4.53 million in fiscal year 2024. In Q2 2026 revenue was $318,000.
$1.74 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Tango Therapeutics, Inc. (TNGX), AbCellera Biologics Inc. (ABCL), Recursion Pharmaceuticals, Inc. (RXRX), Evotec SE (EVO).